NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $14.04 +0.41 (+2.97%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADMA Biologics Stock (NASDAQ:ADMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$13.57▼$14.2050-Day Range$8.61▼$13.6852-Week Range$7.21▼$20.46Volume1.36 million shsAverage Volume4.14 million shsMarket Capitalization$3.11 billionP/E Ratio18.23Dividend YieldN/APrice Target$17.50Consensus RatingModerate Buy Company Overview ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida. Its products are marketed in the United States. Founded in 2004, ADMA has focused on expanding access to plasma-derived treatments. Adam Grossman, a company co-founder, has served as its chief executive officer.AI Generated. May Contain Errors. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreADMA MarketRank™: 4.024926686215 of 5 starsADMA Biologics scored higher than 80% of companies evaluated by MarketBeat, and ranked 79th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialADMA Biologics has a consensus price target of $17.50, representing about 28.4% upside from its current price of $13.63.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.88% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 4.88% in the coming year, from $0.82 to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 17.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.24.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 17.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.97.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.38% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 7.11.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 7.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentADMA Biologics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ADMA Biologics this week, compared to 8 articles on an average week.Search Interest23 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 229% compared to the previous 30 days.MarketBeat Follows6 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $139,200.00 in company stock.Percentage Held by Insiders3.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADMA Stock News HeadlinesADMA Biologics (NASDAQ:ADMA) Director Sells $139,200.00 in StockNovember 17 at 4:22 AM | insidertrades.comADMA Biologics Earnings Call Signals Stronger GrowthNovember 16 at 2:35 PM | theglobeandmail.comGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold. Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program. With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district.November 18 at 1:00 AM | Wall Street Logic (Ad)ADMA Biologics: Ending 2026 On A High NoteNovember 11, 2026 | seekingalpha.comADMA Biologics (NASDAQ:ADMA) Price Target Raised to $13.00November 8, 2026 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Shares Gap Up After Better-Than-Expected EarningsNovember 7, 2026 | americanbankingnews.comCanaccord Genuity Keeps Their Buy Rating on ADMA Biologics (ADMA)November 6, 2026 | theglobeandmail.comQ3 Earnings Beat Might Change The Case For ADMA Biologics StockNovember 6, 2026 | finance.yahoo.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $18.24 at the start of the year. Since then, ADMA stock has decreased by 25.3% and is now trading at $13.63. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 4th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.20 by $0.03. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. Read the conference call transcript. When did ADMA Biologics IPO? ADMA Biologics (ADMA) raised $30 million in an initial public offering (IPO) on the week of November 10th 2014. The company issued 3,352,941 shares at $8.50-$9.50 per share. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional investors include State Street Corp (6.11%), First Trust Advisors LP (4.48%), Goldman Sachs Group Inc. (1.27%) and Nantahala Capital Management LLC (1.16%). Insiders that own company stock include Adam S Grossman, Steve Elms, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade and Lawrence P Guiheen. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Ford Motor (F), Micron Technology (MU) and Viking Therapeutics (VKTX). Company Calendar Last Earnings11/04/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, ADMA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees647Year Founded2004Price Target and Rating Average Price Target for ADMA Biologics$17.50 High Price Target$21.00 Low Price Target$13.00 Potential Upside/Downside+25.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.77 Trailing P/E Ratio18.15 Forward P/E Ratio16.25 P/E GrowthN/ANet Income$146.93 million Net Margins35.14% Pretax Margin45.18% Return on Equity42.56% Return on Assets26.96% Debt Debt-to-Equity Ratio0.45 Current Ratio6.04 Quick Ratio3.25 Sales & Book Value Annual Sales$510.17 million Price / Sales6.08 Cash Flow$0.68 per share Price / Cash Flow20.59 Book Value$1.98 per share Price / Book7.06Miscellaneous Outstanding Shares221,850,000Free Float213,202,000Market Cap$3.10 billion OptionableOptionable Beta0.65 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ADMA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just...Pennie Financial | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.